Last updated: February 19, 2026
What Are the Patentability Criteria for Biopharmaceuticals in South Korea?
South Korea's patent system evaluates biopharmaceutical patents based on novelty, inventive step, and industrial applicability. The following parameters define patentability:
-
Novelty: The invention must be new at the filing date. Prior disclosures, including publications and public uses, negate novelty. The Korean Patent Act explicitly excludes disclosures made within 12 months before filing from destroying novelty, aligning with the grace period provisions.
-
Inventive step: The invention must not be obvious to a person skilled in the technical field. Obviousness is assessed considering prior art, which includes patents, publications, or existing knowledge.
-
Industrial applicability: The invention must be capable of being produced or used in industry.
-
Biological material: For inventions involving biological materials, South Korea requires that the biological material be sufficiently described and, in some cases, deposited in an international or national depositary.
-
Iso- or gene sequences: Patent applications involving genetic sequences must contain a clear description and sequence listings. South Korea adheres to WIPO ST.26 standards for sequence disclosures.
What Are the Enforceability Factors for Biopharmaceutical Patents in South Korea?
Enforceability depends on several factors:
-
Patent validity: Validity issues relate to failure to meet patentability requirements, insufficient disclosure, or added matter violations. Notably, South Korea strictly monitors enablement and written description requirements, particularly for complex biotechnologies.
-
Patent scope: Broader claims enhance enforceability but are more susceptible to invalidation if not supported adequately.
-
Prior art challenges: Both third parties and patent examiners can challenge patents based on prior art. Multiple validity challenges are common, especially for biopharmaceutical inventions involving naturally occurring substances or known gene sequences.
-
Infringement: Enforceability requires that the patent claims are clear and specific enough for third parties to avoid infringement. The courts may scrutinize formulations involving biological or genetic material to confirm infringement only if the scope of the claims is well-defined.
-
Patent term: The standard patent term is 20 years from filing, with possible extensions for drug regulatory approval delays.
How Is the Scope of Claims for Biopharmaceutical Patents Defined?
Claims in South Korean biopharmaceutical patents generally fall into one or more of the following categories:
-
Product claims: Cover active ingredients, biological molecules, or genetic materials. Examples include claims for a specific monoclonal antibody or gene sequence.
-
Use claims: Cover methods of using the biopharmaceutical for treating certain conditions.
-
Process claims: Cover manufacturing processes for the biological product.
-
Formulation claims: Cover specific pharmaceutical compositions involving the biological material.
Scope considerations:
-
Structural claims: Must describe the biological or genetic structure clearly. For example, sequence claims must specify nucleotide or amino acid sequences accurately.
-
Method claims: Should specify the steps involved precisely. Broad method claims are more vulnerable to prior art challenges but offer greater enforceability.
-
Functional claims: Often used for biopharmaceuticals; these claims specify what the biological molecule does, but South Korea tends to favor structural over functional claims due to their clarity.
-
Claim breadth: Overly broad claims risk invalidation. Claims must be supported by the description and sufficiently detailed.
-
Dependent claims: These narrow the scope and provide fallback positions if broader claims are invalidated.
Specific Policy and Practice Considerations
-
South Korea emphasizes sufficient disclosure to support claims, especially for complex biotechnologies. Patent specifications require detailed descriptions, often with experimental data, to demonstrate the invention's feasibility.
-
For gene-related inventions, deposit of biological material in an authorized depository is typically required to satisfy enablement and written description requirements.
-
Patent applications involving naturally occurring substances still face strict novelty and inventive step hurdles, especially if the substance can be isolated or characterized without inventive effort.
-
Amendment rules restrict claims during prosecution to avoid extending beyond the original disclosure, which impacts scope management.
Summary Table of Key Points
| Aspect |
Details |
| Patentability criteria |
Novelty, inventive step, industrial applicability |
| Biological material |
Deposit often required; sufficient description needed |
| Sequence disclosures |
WIPO ST.26 standards; clear, complete listings |
| Enforceability |
Validity based on patent scope, prior art challenges, proper disclosure |
| Claim scope |
Product, use, process, formulation; backed by detailed description |
| Claim breadth |
Should balance broad protection with risk of invalidation |
Key Takeaways
- Patents in South Korea require rigorous disclosure, especially for gene and biological material claims.
- Patent validity challenges frequently target scope and inventive step.
- Broader claims enhance enforceability but increase invalidation risk if unsupported.
- Detailed description, deposit of biological material, and precise claim language are critical.
- The legal environment favors structural claims over functional claims due to clarity concerns.
FAQs
1. Can naturally occurring genes be patented in South Korea?
Yes, but only if isolated, characterized, and if the invention involves a novel, inventive step beyond mere discovery.
2. Is a deposit of biological material mandatory when filing a patent application?
Typically, yes, especially when claiming biological or genetic materials, to meet enablement and written description requirements.
3. How broad can claims be for biopharmaceuticals in South Korea?
Claims should be supported by the description. Broad claims risk invalidation; narrower claims are safer but offer less protection.
4. What are common grounds for patent invalidation in biopharma cases?
Lack of novelty, obviousness, insufficient disclosure, or claims extending beyond the original disclosure.
5. How does South Korea treat patent term extensions for biopharmaceuticals?
Extensions are granted during regulatory approval delays, similar to other jurisdictions, up to five years.
[1] Korean Intellectual Property Office (KIPO). (2023). Patent examination guidelines for biotechnology.
